metricas
covid
Buscar en
Cirugía Española (English Edition)
Toda la web
Inicio Cirugía Española (English Edition) Treatment in Esophagogastric Junction Cancer: Past, Present and Future
Información de la revista
Vol. 97. Núm. 8.
Páginas 459-464 (octubre 2019)
Visitas
7261
Vol. 97. Núm. 8.
Páginas 459-464 (octubre 2019)
Update on the Multidisciplinary Management of Esophagogastric Junction Cancer
Acceso a texto completo
Treatment in Esophagogastric Junction Cancer: Past, Present and Future
Tratamientos oncológicos en el cáncer de unión esofagogástrica: pasado, presente y futuro
Visitas
7261
Carles Pericaya,
Autor para correspondencia
cpericay@gmail.com

Corresponding author.
, Ismael Macías-Declaraa, Virginia Arrazubib, Laia Vilàa, Miguel Marínc
a Servicio Oncología Médica, Hospital de Sabadell-Corporació Sanitària Parc Taulí, Sabadell, Barcelona, Spain
b Servicio Oncología Médica, Hospital de Navarra, Pamplona, Navarra, Spain
c Servicio Oncología Médica, Hospital Virgen de la Arrixaca, Murcia, Spain
Este artículo ha recibido
Información del artículo
Resumen
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Tablas (2)
Table 1. Clinical Trials Analyzing Preoperative and Perioperative Treatment With Chemotherapy and Radiochemotherapy Including Patients With Adenocarcinoma of the EGJ.
Table 2. Clinical Trials Analyzing Postoperative Adjuvant Treatment With Chemotherapy and Radiochemotherapy Including Patients With Adenocarcinoma of the EGJ.
Mostrar másMostrar menos
Abstract

Adenocarcinomas of the gastroesophageal junction represent 27% of all gastric tumors. In recent years, it has been classified as an entity of its own, with specific treatments that are sometimes differentiated from gastric treatments. Treatment can be based on chemotherapy (CTx) or chemoradiotherapy (CRTx) that is administered preoperatively (neoadjuvant), postoperatively (adjuvant) or perioperatively. There are studies that have tested several treatment modalities, but there is currently no single protocolized sequence. The results point to an improvement in survival when we administer preoperative treatment, with evidence in favor of CRTx and CTx. Studies are already underway with targeted treatment that aim to increase the activity of traditional chemotherapy. In the next few years, we should know the role of immunotherapy in this group of patients.

Keywords:
Gastric cancer
Gastroesophageal junction cancer
Neoadjuvant treatment
Adjuvant treatment
Perioperative treatment
Resumen

Los adenocarcinomas de la unión esofagogástrica representan un 27% de todos los tumores gástricos. En los últimos años se está clasificando como una entidad propia, con tratamientos específicos y en ocasiones diferenciados de los tratamientos de los adenocarcinomas de cuerpo gástrico. El esquema de tratamiento puede basarse en quimioterapia (QT) o quimiorradioterapia (QTRT), que se administra de forma preoperatoria (neoadyuvante), postoperatoria (adyuvante) o perioperatoria. Existen estudios que han testado las diversas modalidades de tratamiento, pero en estos momentos no se dispone de una única secuencia protocolizada válida. Los resultados apuntan a una mejoría de la supervivencia cuando administramos tratamiento preoperatorio, con evidencia a favor de la QTRT y de la QT. Ya están en marcha estudios con tratamientos dirigidos que pretenden conseguir aumentar la actividad de la QT tradicional y en los próximos años deberemos conocer el papel de la inmunoterapia en este grupo de pacientes.

Palabras clave:
Cáncer gástrico
Cáncer de la unión esofagogástrica
Tratamiento neoadyuvante
Tratamiento adyuvante
Tratamiento perioperatorio
Texto completo
Introduction

In 2012, gastric cancer (GC) had an incidence of 951000 cases worldwide, making it the fifth cause of cancer and the third cause of cancer death with 723000 cases.1 In Spain, it is the sixth most frequent type of cancer, with 7810 new cases and 5389 deaths annually.2

GC can be differentiated into 2 topographic categories3: cardia or esophagogastric junction (EGJ),4 and non-cardia or rest of the stomach. Both tumors have differentiated risk factors.

EGJ tumors represent 27% of GC (30% men; 21% women), with an incidence of 3.3/100000 inhabitants (5.3 men; 1.6 women).5

Despite R0 surgery, there is a high incidence of local recurrence and distant recurrence. These results have led to the evaluation of therapies combined with chemotherapy (CTx) and radiotherapy (RTx) as neoadjuvant, perioperative or adjuvant treatment, although the best strategy has not been established.

The aim of this review is to provide a thorough overview of the oncological treatments available for the multimodal treatment of adenocarcinomas of the EGJ.6

Preoperative Treatment

In EGJ cancer, both CTx and neoadjuvant chemoradiotherapy (CRTx) have been studied (Table 1). The meta-analysis by Gebski et al.7 analyzed neoadjuvant CTx (CTNeo) (8 studies; 1724 patients) and preoperative CRTx (CRTNeo) (10 studies; 1209 patients), showing an absolute benefit in overall 2-year survival (OS) of 7% for CTx and 13% for CRTx. Both treatments improved survival (CRTx [P=.02] and CTx [P=.014]) in the case of adenocarcinoma, but only CRTx showed benefits in patients with squamous carcinoma (P=0.04). The phase III trial CALBG 97818 compared initial surgery with CTx (CDDP+5-FU) and RTx followed by surgery. It recruited 56 of the 475 patients planned, managing to demonstrate a benefit in OS of 4.48 years compared to 1.79 years (P=.002).

Table 1.

Clinical Trials Analyzing Preoperative and Perioperative Treatment With Chemotherapy and Radiochemotherapy Including Patients With Adenocarcinoma of the EGJ.

Study  N  TNM  Tx  PFS  SG 
Intergroup 011621,22  55620% EGJ  T1-2 175T3 346T4 38N0 83N+476  D0 299D1 198D2 54(20%)  FU/LV+RTObs  HR 1.51 (1.25–1.83)P<.001  HR 1.32 (95%CI 1.10–1.60)P=.0046 
CALGB 8010123  54622% EGJ  T1-2 252T3 259T4 23N0 77N+454  D0 61D1 175D2 299  ECF-FU/LV/RT-ECFFU/LV/RT  5-Year PFS37% vs 39%HR 0.96 (95%CI 0.77–1.20)  5-Year OS44% vs 44%HR 0.98 (95%CI 0.78–1.24) 
CRITICS24  77817% EGJ  T1 87T2 222T3 217T4 63N0311N+291  D1 78D1+501D2 40  ECX/EOX-XRTECX/EOX ECX/EOX  5-Year PFS39% vs 38%HR 0.99 (95%CI 0.82–1.9)P=.92  5-Year OS40.8% vs 40.9%HR 1.01(95%CI 0.84–1.22); P=.90 
ARTIST25  4585% EGJ  T2 99T3-4 306N0 62N+396  D2  XP-XRT-XPXP  4-Year PFS 78.2% vs 74.2%(HR 0.74; 95%CI 0.52–1.05 P=.0862)   
CLASSIC28,29  10353% EGJ  T1 11T2 564T3 456T4 4N0 103N+932  D2  CAPOXObs  3-Year PFS74% vs 59%HR 0.56 (95%CI, 0.44–0.72)  5-Year OS78% vs 69%HR 0.66(95%CI, 0.51–0.85) 
Neoadjuvant Chemoradiotherapy

In subsequent studies and meta-analyses,9 the hypothesis of neoadjuvant treatment being beneficial was maintained, and in 2012 the CROSS10 phase III study validated the CRTNeo strategy. The study included 368 patients (24% EGJ); CTNeo (CBCA-paclitaxel) and concomitant RTx followed by surgery were compared with surgery alone. The OS was 49 months versus 24 months in favor of CRTNeo treatment (P=.003). R0 resections were 92% versus 69% in favor of CRTNeo (P<.001), and the morbidity and mortality rates were the same in both treatment arms.

Neoadjuvant Chemotherapy

The phase III OE02 trial11 recruited 802 patients with esophageal and EGJ cancer (10%) and compared direct surgery with CTNeo (cisplatin-5-FU) followed by surgery. The trial demonstrated a benefit in 5-year OS of 23% versus 17% in favor of neoadjuvant therapy (P=.03). The phase III OE05 trial compared cisplatin-5-FU with the neoadjuvant epirubicin-cisplatin-capecitabine (ECF) triplet followed by surgery and showed no benefit for triple therapy. A meta-analysis published by Sjoquist et al.9 confirmed the benefit in OS for CTNeo of 5.1% after 2 years (P=.005), which was shown in patients with adenocarcinoma (P=.01) but not in the squamous carcinoma group (P=.18).

Chemoradiotherapy Versus Preoperative Chemotherapy

In a study specifically aimed at patients with adenocarcinoma of the EGJ,12 126 patients out of 354 were included. CTNeo (cisplatin+5-FU) and subsequent surgery were compared to CRTNeo followed by surgery. The 3-year OS (47.4% vs 27.7%; P=.07) and 5-year OS13 (P=.055), although higher in the CRTx group, did not reach statistically significant differences. Perioperative mortality was also higher in the CRTx group (10.2% vs 3.8%). A second study14 included 181 patients (18% EGJ), comparing CTNeo (cisplatin-5-FU) versus CRTNeo. The CRTNeo arm showed a higher rate of pathological complete responses (pRC) (28% vs 9%; P=.002) and R0 resections (87% vs 74%; P=.004), although OS was similar in both groups.

Therefore, the benefit of neoadjuvant treatment has consistent evidence, although there is still controversy about the most beneficial strategy.

Due to the benefit of trastuzumab treatment in patients who overexpress HER2 in the metastatic stage,15 the phase II-III INNOVATION study (NCT02205047) (CTx+trastuzumab±neoadjuvant pertuzumab) and the phase II trial (NCT01196390) (RTx-carboplatin-taxol±trastuzumab) are underway to demonstrate the potential effect of these therapies in the treatment of these tumors.

Cetuximab (anti-EGFR monoclonal antibody) added to CRTNeo showed no benefit in OS in the phase II-III SCOPE116 trial or in the phase III RTOG 0436 trial.17 Bevacizumab (anti-VEGF monoclonal antibody) has also demonstrated no activity in a phase II study18 comparing bevacizumab and erlotinib associated with CRTNeo (CBDCA-paclitaxel-5-FU).

Current trials are evaluating the effectiveness of other immunotherapeutic drugs in neoadjuvant therapy, such as nivolumab and ipilimumab (NCT03604991), and pembrolizumab (NCT02730546).

Adjuvant Treatment

OS after the resection of EGJ tumors ranges between 18 and 50%,19 with a recurrence rate of more than 50%. Therefore, the use of adjuvant treatment is often necessary.20

There are studies that evaluate adjuvant treatment with CTx (CTAdj) or CRTx (CRTAdj) (Table 2).

Table 2.

Clinical Trials Analyzing Postoperative Adjuvant Treatment With Chemotherapy and Radiochemotherapy Including Patients With Adenocarcinoma of the EGJ.

Study  N  TNM  Tx  PFS  OS 
MAGIC33  50315% EGJ  Stage II-IVa  ECFx3-Cir-ECFx3Surgery    36% vs 24%HR 0.75, P=.00936 months vs 23 months (5 yrs) 
FNLCC/FFCD34  22464% EGJ  Stage II-IVa  CFx2-3-Cir-CFx3-4Surgery  5-Year PFS37% vs 39%HR 0.65  OS 5.7 years38% vs 24%HR 0.69; P=.02 
EORTC 409549  144/360  Stage III-IVa  CF-SurgerySurgery    OS 4.4 yearsHR 0.84P=.466 
FLOT435  71656% EGJ  Stage  FLOTx4-Cir-FLOTx4ECFx3-Cir-ECFx3    OS 5 years45% vs 36%50 months vs 35 months 
POET13  126/354100% EGJ    CF-CirCF-CVP16/RT-Cir  3-Year PFSP=.000317  5-year OS40% vs 24%HR 0.65P=.003 
CROSS10  36311% EGJ    Taxol/CBDCA/RTP-CirSurgery    5-year OS47% vs 33%HR 0.67 
Adjuvant Chemoradiotherapy

The SWOG 9008/INT-0116 trial evaluated the efficacy of surgery followed by CRTAdj in the OS of patients with resectable adenocarcinoma of the stomach or UGE (20%).21 The 10-year OS was beneficial for CRTAdj (27 months vs 36 months; P=.0046). Local recurrence (19% vs 27%) benefited from CRTAdj.22 These results have standardized CRTAdj in GC or completely resected EGJ without preoperative treatment.

The CALGB 80101 study evaluated 546 patients (22% EGJ)23 and compared 5 FU to the ECF scheme associated with RTx. No differences were found in OS after 6.5 years (44% vs 44%; HR 0.98) or in progression-free survival (PFS) (37% vs 39%; HR 0.96).

The CRITICS study included 17% EGJ tumors.24 It compared the ECX/EOX regimen with adjuvant CRTx, with no differences in 5-year OS (40.8% for CTx vs 40.9% for CRTx).

The ARTIST study compared CTx with cisplatin and capecitabine (XP) with CRTx (XP-XRT-XP),25 including only 3% of EGJ tumors. There were no differences in OS (HR: 1.13) or recurrences (P=.0862). Patients with positive lymph nodes presented a 3-year PFS that favored CRTAdj (76% vs 72%; P=.0365). Currently, the ARTIST-2 study is testing the benefit in patients with positive lymph nodes.

While the addition of CRTAdj has been associated with benefits in survival in patients with EGJ cancer with positive lymph nodes,26,27 the efficacy of postoperative CRTx compared to surgery alone has not been demonstrated in a randomized trial.

Adjuvant Chemotherapy

There are more than 30 randomized studies that compare adjuvant CTx with surgery alone in resected GC. The results of the majority were negative for improving OS and do not provide data for EGJ tumors.

In the CLASSIC Asian study of patients with gastric adenocarcinoma (3% EGJ) with D2 lymphadenectomy,28 CTAdj (capecitabine+oxaliplatin) was compared with surgery alone. The 3-year PFS (74% vs 59%; HR: 0.56) and 5-year OS benefited the CTAdj group (78% vs 69%), and the patients with the greatest benefit were those with lymph node involvement.29

Meta-analyses30,31 give a better prognosis to Asian patients, with a 15% lower risk of death when they were treated with CTAdj (HR: 0.85).32

Perioperative Chemotherapy

There are 4 relevant studies about perioperative chemotherapy treatment versus surgery alone in patients diagnosed with GC (Table 1).

The MAGIC33 study included patients with potentially resectable adenocarcinoma of the stomach (74%), distal esophagus (15%) and EGJ (11%). CTx (perioperative ECFx6) was compared with surgery alone and achieved greater R0 surgery (79% vs 70%), T1/2 tumors (52% vs 37%), N0 disease (84% vs 71%) and 5-year OS of 36% versus 23% of the surgery alone group.

The French FNCLCC/FFCD study34 (144 EGJ) studied perioperative CTx with cisplatin-5-FU versus surgery alone. The 5-year PFS (34% vs 19%) and OS (38% vs 24%) favored CTx.

A meta-analysis9 concluded that CTNeo increased OS (HR: 1.32) and PFS (HR: 1.85).

The phase III study FLOT4-AIO35 compared FLOT perioperative FLOT treatment (docetaxel+oxaliplatin+5-FU) with ECF/ECX and randomized 716 patients with gastric (44%) and EGJ (56%) cancer. FLOT was significantly better in pRC (16% vs 8%), T0/T1 (25% vs 15%), N0 (49% vs 41%) and 5-year OS (45% vs 36%). Postoperative complications were similar. These results have made the FLOT regimen a standard in perioperative treatment.

Currently, immunotherapy treatment is being tested in perioperative (NCT03221426, NCT03421288) and adjuvant (NCT2743494, NCT03006705) strategies.

Stage iv Treatment (Metastasis)

EGJ tumors have been included in studies exploring the treatment of stage IV gastric adenocarcinoma. A Cochrane review36 demonstrated the benefit in OS of treatment with CTx compared to the best support treatment (4.3 vs 11 months).

The drugs with proven efficacy in metastatic gastric/EGJ cancer are fluoropyrimidines (5-FU, capecitabine), platinum salts (oxaliplatin and cisplatin), taxanes (paclitaxel, docetaxel), irinotecan, TAS 102, monoclonal antibodies trastuzumab and ramucirumab, as well as immunotherapy (pembrolizumab and nivolumab), especially in tumors with microsatellite instability or overexpression of PDL1.

The choice of treatment depends on the general condition and comorbidity of the patient as well as HER2 overexpression in the tumor tissue. Combination treatments with 2 drugs (fluoropyrimidines-platinum) are standard,37 but combinations with 3 drugs (5-FU+platinum+docetaxel, ECF) in patients with excellent general condition, or monotherapy (fluoropyrimidine, irinotecan, taxane weekly) in patients with poor general condition, could be the choice.37

First Line of Treatment

The phase III ToGA trial randomized patients with HER2 overexpression38 (20% EGJ) to cisplatin+5-FU±trastuzumab.16 Both the OS (13.8 vs 11.1 months; P=.0046) and the objective response rate (47% vs 35%; P=.0017) were favorable to the use of trastuzumab. In tumors without HER2 overexpression, the main combined regimens are FOLFOX and CAPOX. The use of triplets39 (cisplatin+docetaxel+5-FU) achieves more responses and PFS with greater toxicity. The contribution of anthracyclines and irinotecan does not show a clear benefit in the PFS or OS.40 Anti-EGFR monoclonal antibodies (cetuximab, panitumumab) or anti-VEGF/VEGF-R (bevacizumab, ramucirumab, aflibercept) have not demonstrated activity.

Second Line of Treatment

Other treatments are weekly paclitaxel, docetaxel or irinotecan.41 The paclitaxel+ramucirumab combination (RAINBOW42 phase III study with 20% of EGJ tumors) presented a PFS of 4.4 versus 2.9 months and an OS of 9.6 months versus 7.4 months (P=.017) in favor of adding ramucirumab to taxol, becoming the second-line treatment of choice.37

Immunotherapy

The utility of immunotherapy has been demonstrated in the metastatic stage,43 with pembrolizumab and nivolumab in the KEYNOTE-59,44 KEYNOTE-6145 and ATTRACTION-2 studies.46

Conclusions

Adenocarcinoma of the EGJ is an entity that is increasing in incidence, due, in part, to eating habits and behaviors. Localized EGJ tumors can be treated, achieving cure rates higher than tumors of the gastric body. Studies have analyzed surgery and CTx or RTx administered as neoadjuvant, adjuvant or perioperative treatment. However, no strategy has been defined as standard to date. For this reason, the treatment of EGJ adenocarcinoma continues to be a therapeutic challenge for multidisciplinary tumor committees.

Conflict of Interests

The authors have no conflict of interests to declare regarding this manuscript.

References
[1]
K.D. Crew, A.I. Neugut.
Epidemiology of upper gastrointestinal malignancies.
Semin Oncol, 31 (2004), pp. 450-464
[2]
J. Ferlay, M. Colombet, I. Soerjomataram, C. Mathers, D.M. Parkin, M. Piñeros, et al.
Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods.
Int J Cancer, 144 (2019), pp. 1941-1953
[3]
M.B. Amin, F.L. Greene, S.B. Edge, C.C. Compton, J.E. Gershenwald, R.K. Brookland, et al.
The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging.
CA Cancer J Clin, 67 (2017), pp. 93-99
[4]
J.R. Siewert, H.J. Stein.
Carcinoma of the cardia: carcinoma of the gastroesophageal junction classification, pathology and extent of resection.
Dis Esophagus, 9 (1996), pp. 173-182
[5]
A. Colquhoun, M. Arnold, J. Ferlay, K.J. Goodman, D. Forman, I. Soerjomataram.
Global patterns of cardia and non-cardiagastric cancer incidence in 2012.
Gut, (2015), pp. 1-8
[6]
M. Martin-Richard, A. Custodio, C. García-Girón, C. Grávalos, C. Gomez, P. Jimenez-Fonseca, et al.
Seom guidelines for the treatment of gastric cancer 2015.
Clin Transl Oncol, 17 (2015), pp. 996-1004
[7]
V. Gebski, B. Burmeister, B.M. Smithers, K. Foo, J. Zalcberg, J. Simes, et al.
Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis.
Lancet Oncol [Internet], 8 (2007), pp. 226-234
[8]
J. Tepper, M.J. Krasna, D. Niedzwiecki, D. Hollis, C.E. Reed, R. Goldberg, et al.
Phase III trial of trimodality therapy with cisplatin, fluorouracilo, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
J Clin Oncol [Internet], 26 (2008), pp. 1086-1092
[9]
K.M. Sjoquist, B.H. Burmeister, B.M. Smithers, J.R. Zalcberg, R.J. Simes, A. Barbour, et al.
Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis.
Lancet Oncol, 12 (2011), pp. 681-692
[10]
J. Shapiro, J.J.B. van Lanschot, M.C.C.M. Hulshof, P. van Hagen, M.I. van Berge Henegouwen, B.P.L. Wijnhoven, et al.
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Lancet Oncol, 16 (2015), pp. 1090-1098
[11]
W.H. Allum, S.P. Stenning, J. Bancewicz, P.I. Clark, R.E. Langley.
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
J Clin Oncol, 27 (2009), pp. 5062-5067
[12]
M. Stahl, M.K. Walz, M. Stuschke, N. Lehmann, H.J. Meyer, J. Riera-Knorrenschild, et al.
Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction.
J Clin Oncol, 27 (2009), pp. 851-856
[13]
M. Stahl, M.K. Walz, J. Riera-Knorrenschild, M. Stuschke, A. Sandermann, M. Bitzer, et al.
Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction (POET): long-term results of a controlled randomised trial.
Eur J Cancer, 81 (2017), pp. 183-190
[14]
F. Klevebro, G. Alexandersson von Döbeln, N. Wang, G. Johnsen, A.B. Jacobsen, S. Friesland, et al.
A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction.
Ann Oncol, 27 (2016), pp. 660-667
[15]
Y.-J. Bang, E. van Cutsem, A. Feyereislova, H.C. Chung, L. Shen, A. Sawaki, et al.
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Lancet (London, England), 376 (2010), pp. 687-697
[16]
T. Crosby, C.N. Hurt, S. Falk, S. Gollins, J. Staffurth, R. Ray, et al.
Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial.
Lancet Oncol, 14 (2013), pp. 627-637
[17]
M. Suntharalingam, K. Winter, D. Ilson, A.P. Dicker, L. Kachnic, A. Konski, et al.
Effect of the addition of cetuximab to paclitaxel cisplatin, and radiation therapy for patients with esophageal cancer: the NRG Oncology RTOG 0436 phase 3 randomized clinical trial.
JAMA Oncol, 3 (2017), pp. 1520-1528
[18]
J.C. Bendell, A. Meluch, J. Peyton, M. Rubin, D. Waterhouse, C. Webb, et al.
A phase ii trial of preoperative concurrent chemotherapy/radiation therapy plus bevacizumab/erlotinib in the treatment of localized esophageal cancer.
Clin Adv Hematol Oncol, 10 (2012), pp. 430-437
[19]
E.I. Sihvo, M.E. luostarinen, J.A. Salo.
Fate of patients with adenocarcinoma of the esophagus and the esophagogastric junction: a population-based analysis.
Am J Gastroenterol, 99 (2004), pp. 419-424
[20]
L.L. Gunderson, H. Sosin.
Adenocarcinoma of the stomach: areas of failure in a reoperation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy.
Int J Radiat Oncol biol Phys, 8 (1982), pp. 1-11
[21]
J.S. Macdonald, S.R. Smalley, J. Bennedetti, S.A. Hundahl, N.C. Estes, G.N. Stemmermann, et al.
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
N Engl J Med, 345 (2001), pp. 725
[22]
S.R. Smalley, J. Bennedetti, D.G. Haller, S.A. Hundahl, N.C. Estes, J.A. Ajani, et al.
Update analysis of SWOG-directed intergroup study 0116: a phase iii trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection.
J Clin Oncol, 30 (2012), pp. 2327
[23]
C.S. Fuchs, D. Niedzwiecki, H.J. Mamon, J.E. Tepper, X. Ye, R.S. Swanson, et al.
Adjuvant chemoradiotherapy with epirubicin, cisplatin, and fluorouracil compared with adjuvant chemoradiotherapy with fluorouracil and leucovorin after curative resection of gastric cancer: results from CALGB 80101 (Alliance).
J Clin Oncol, 1035 (2017), pp. 3671-3677
[24]
A. Cats, E.P.M. Jansen, N.C.T. van Grieken, K. Sikorska, P. Lind, M. Nordsmark, et al.
Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial.
Lancet Oncol, 19 (2018), pp. 616-628
[25]
J. Lee, D.H. Lim, S. Kim, S.H. Park, J.O. Park, Y.S. Park, et al.
Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial.
J Clin Oncol, 30 (2012), pp. 268-273
[26]
E.L. Bedard, R.I. Inculet, R.A. Malthaner, E. Brecevic, M. Vincent, R. Dar.
The role of surgery and postoperative chemoradiation therapy in patients with lymph node positive esophageal carcinoma.
Cancer, 91 (2001), pp. 2423-2430
[27]
T.W. Rice, D.J. Adelstein, M.A. Chidel, L.A. Rybicki, M.M. DeCamp, S.C. Murthy, et al.
Benefit of postoperative adjuvant chemoradiotherapy in locorregionally advanced esophageal carcinoma.
J Thorac Cardiovasc Surg, 126 (2003), pp. 1590-1596
[28]
Y.J. Bang, Y.W. Kim, H.K. Yang.
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Lancet, 379 (2012), pp. 315-321
[29]
S.H. Noh, S.R. Park, H.K. Yang, H.C. Chung, I.J. Chung, S.W. Kim, et al.
Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow up of an open-label, randomised phase iii trial.
Lancet Oncol, 15 (2014), pp. 1389
[30]
U. Ronellenfitsch, M. Schwarzbach, R. Hofheinz, P. Kienle, M. Kieser, T.E. Slanger, et al.
Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus.
Cochrane Database Syst Rev, 5 (2013),
[31]
C.C. Earle, J.A. Maroun.
Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials.
Eur J Cancer, (1999), pp. 1059
[32]
R. Diaz-Nieto, R. Orti-Rodríguez, M. Winslet.
Post-surgical chemotherapy versus surgery alone for resectable gastric cancer.
Cochrane Database Syst Rev, (2013),
[33]
D. Cunningham, W.H. Allum, S.P. Stenning, J.N. Thompson, C.J. Van de Velde, M. Nicolson, et al.
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
N Engl J Med, 355 (2006), pp. 11-20
[34]
M. Ychou, V. Boige, J.P. Pignon, T. Conroy, O. Bouché, G. Lebreton, et al.
Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal denocarcinoma: an FNCLCC and FFCD multicenter phase iii trial.
J Clin Oncol, 29 (2011), pp. 1715
[35]
S.E. Al-Batran, N. Homann, C. Pauligk, G. Illerhaus, U.M. Martens, J. Stoehlmacher, et al.
Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracilo/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracilo or capecitabine (ECF/ECX) for resectable gastric or gastroesophage al junction (GEJ) adenocarcinoma (FLOT4-AIO): a multicenter, randomized phase 3 trial [abstract].
J Clin Oncol, 35 (2017),
[36]
A.D. Wagner, N.L. Syn, M. Moehler, W. Grothe, W.P. Yong, B.C. Tai, et al.
Chemotherapy for advanced gastric cancer.
Cochrane Database Syst Rev, 8 (2017),
[37]
C. Pericay, F. Rivera, C. Gomez-Martin, I. Nuñez, A. Cassinello, E.R. Imedio.
Positioning of second-line treatment for advanced gastric and gastroesophageal junction adenocarcinoma.
Cancer Med, 5 (2016), pp. 3464-3474
[38]
J. Niu, J. Weber, D. Gelbspan.
Change of HER2 status in metastatic esophageal adenocarcinoma: heterogeneity of the disease? Case report and review of literature.
J Gastrointest Oncol, 3 (2012), pp. 358-361
[39]
E. Van Cutsem, V.M. Moiseyenko, S. Tjulandin, A. Majlis, M. Constenla, C. Boni, et al.
Phase III study of docetaxel and cisplatin plus fluorouracilo compared with cisplatin and fluorouracilo as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
J Clin Oncol, 24 (2006), pp. 4991
[40]
E. Ter Veer, N. Haj Mohammad, G. van Valkenhoef, L.L. Ngai, R.M.A. Mali, M.C. Anderegg, et al.
The efficacy and safety of first-line chemotherapy in advanced esophagogastric cancer: a network meta-analysis.
J Natl Cancer Inst, 108 (2016),
[41]
S. Hironaka, S. Ueda, H. Yasui, T. Nishina, M. Tsuda, T. Tsumura, et al.
Randomized, open-label, phase iii study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metástasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial.
J Clin Oncol, 31 (2013), pp. 4438
[42]
H. Wilke, K. Muro, E. van Cutsem, S.C. Oh, G. Bodoky, Y. Shimada, et al.
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.
Lancet Oncol, 15 (2014), pp. 1224
[43]
K. Muro, H.C. Chung, V. Shankaran, R. Geva, D. Catenacci, S. Gupta, et al.
Pembrolizumab for patients with PDL1-positive advanced gastric cancer (KEYNOTE-012) multicentre, open-label, phase 1b trial.
Lancet Oncol, 17 (2016), pp. 717-726
[44]
Y.J. Bang, Y.K. Kang, D.V. Catenacci, K. Muro, C.S. Fuchs, R. Geva, et al.
Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study.
[45]
K. Shitara, M. Özgüroğlu, Y.J. Bang, M. Di Bartolomeo, M. Mandalà, M.H. Ryu, et al.
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial.
[46]
Y.K. Kang.
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Please cite this article as: Pericay C, Macías-Declara I, Arrazubi V, Vilà L, Marín M. Tratamientos oncológicos en el cáncer de unión esofagogástrica: pasado, presente y futuro. Cir Esp. 2019;97:459–464.

Copyright © 2019. AEC
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos